Nasopax Uno Kamilla (Oxymetazoline Hydrochloride)

Oxymetazoline is a selective alpha‑1 adrenergic receptor agonist. By stimulating these receptors on the blood vessels of the nasal lining, it causes vasoconstriction, which decreases mucosal edema and opens the nasal airway for easier breathing.

The exact dosing regimen is determined by a qualified prescriber. Typically, one or two sprays per nostril are administered every 8 to 12 hours, not exceeding the maximum daily frequency recommended on the product label.

Safety data are limited. Use only if the potential benefit justifies any possible risk to the fetus or infant. Pregnant or nursing individuals should discuss use with their healthcare provider before starting treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with phenylephrine‑based sprays, oxymetazoline generally offers a longer duration of action (up to 12 hours) and stronger vasoconstriction, which can result in fewer applications per day. Both classes share similar safety considerations, but oxymetazoline is often preferred for its prolonged effect.

Store the nasal spray at room temperature, below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use to maintain product stability.

The product is administered as a nasal spray. Tilt the head slightly forward, insert the nozzle into one nostril, and press the pump to deliver the prescribed number of sprays. Repeat in the other nostril if directed, and avoid blowing the nose immediately after application.

Serious adverse events include hypertension, tachycardia, cardiac arrhythmias, severe nasal ulceration, and rebound congestion (rhinitis medicamentosa) when used longer than recommended. Patients should seek medical attention if they experience persistent high blood pressure, rapid heart rate, or significant nasal tissue damage.

Contraindications include individuals with severe hypertension, coronary artery disease, hyperthyroidism, those taking monoamine oxidase inhibitors, and children younger than six years. Anyone with known hypersensitivity to oxymetazoline or any component of the formulation should also avoid using the product.